Alterations in neuronal excitability and the potency of spinal mu, delta and kappa opioids after carrageenan-induced inflammation. 1992

Louise C Stanfa, and Ann F Sullivan, and Anthony H Dickenson
Department of Pharmacology, University College London, London WC1E 6BT, UK.

These electrophysiological results show that the development of inflammation following peripheral injection of carrageenan into the paw is accompanied by alterations in the magnitude of the C-fibre evoked response of multireceptive dorsal horn neurones. The evoked response of the dorsal horn cells was found to either increase or decrease in the 3 h following the carrageenan injection, and the direction of this change was related to the degree of wind-up exhibited by the cell. Regardless of whether a cell was facilitated or inhibited by carrageenan, mu, delta and kappa opioids applied topically onto the spinal cord (equivalent to an intrathecal injection) exhibited increased antinociceptive potency. This increased effectiveness was especially marked for the mu opioid, morphine, which showed a 30-fold increase in potency. Interestingly the facilitations seen with the lowest doses of the mu and kappa opioids in this model in normal animals were absent after carrageenan. In addition, a very low dose of spinal naloxone caused a small but significant reduction in the C-fibre evoked responses. These results demonstrate that following peripheral inflammation, functional changes develop in both spinal transmission and modulatory systems. Alterations in the antinociceptive potency of opioid agonists occurs, with the mu agonist, morphine, showing the greatest change.

UI MeSH Term Description Entries
D007278 Injections, Spinal Introduction of therapeutic agents into the spinal region using a needle and syringe. Injections, Intraspinal,Injections, Intrathecal,Intraspinal Injections,Intrathecal Injections,Spinal Injections,Injection, Intraspinal,Injection, Intrathecal,Injection, Spinal,Intraspinal Injection,Intrathecal Injection,Spinal Injection
D008297 Male Males
D009020 Morphine The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. Morphine Sulfate,Duramorph,MS Contin,Morphia,Morphine Chloride,Morphine Sulfate (2:1), Anhydrous,Morphine Sulfate (2:1), Pentahydrate,Oramorph SR,SDZ 202-250,SDZ202-250,Chloride, Morphine,Contin, MS,SDZ 202 250,SDZ 202250,SDZ202 250,SDZ202250,Sulfate, Morphine
D009187 Myelitis Inflammation of the spinal cord. Relatively common etiologies include infections; AUTOIMMUNE DISEASES; SPINAL CORD; and ischemia (see also SPINAL CORD VASCULAR DISEASES). Clinical features generally include weakness, sensory loss, localized pain, incontinence, and other signs of autonomic dysfunction. Myelopathy, Inflammatory,Spinal Cord Inflammation,Subacute Necrotizing Myelitis,Infectious Myelitis,Inflammation, Spinal Cord,Inflammations, Spinal Cord,Inflammatory Myelopathies,Inflammatory Myelopathy,Myelitides,Myelitides, Subacute Necrotizing,Myelitis, Infectious,Myelitis, Subacute Necrotizing,Myelopathies, Inflammatory,Necrotizing Myelitides, Subacute,Necrotizing Myelitis, Subacute,Spinal Cord Inflammations,Subacute Necrotizing Myelitides
D009270 Naloxone A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. MRZ 2593-Br,MRZ-2593,Nalone,Naloxon Curamed,Naloxon-Ratiopharm,Naloxone Abello,Naloxone Hydrobromide,Naloxone Hydrochloride,Naloxone Hydrochloride Dihydride,Naloxone Hydrochloride, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Narcan,Narcanti,Abello, Naloxone,Curamed, Naloxon,Dihydride, Naloxone Hydrochloride,Hydrobromide, Naloxone,Hydrochloride Dihydride, Naloxone,Hydrochloride, Naloxone,MRZ 2593,MRZ 2593 Br,MRZ 2593Br,MRZ2593,Naloxon Ratiopharm
D009474 Neurons The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM. Nerve Cells,Cell, Nerve,Cells, Nerve,Nerve Cell,Neuron
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D010166 Palliative Care Care alleviating symptoms without curing the underlying disease. (Stedman, 25th ed) Palliative Treatment,Palliative Supportive Care,Palliative Surgery,Palliative Therapy,Surgery, Palliative,Therapy, Palliative,Care, Palliative,Palliative Treatments,Supportive Care, Palliative,Treatment, Palliative,Treatments, Palliative
D011759 Pyrrolidines Compounds also known as tetrahydropyridines with general molecular formula (CH2)4NH. Tetrahydropyridine,Tetrahydropyridines
D002351 Carrageenan A water-soluble extractive mixture of sulfated polysaccharides from RED ALGAE. Chief sources are the Irish moss CHONDRUS CRISPUS (Carrageen), and Gigartina stellata. It is used as a stabilizer, for suspending COCOA in chocolate manufacture, and to clarify BEVERAGES. Carrageenin,iota-Carrageenan,kappa-Carrageenan,lambda-Carrageenan,iota Carrageenan,kappa Carrageenan,lambda Carrageenan

Related Publications

Louise C Stanfa, and Ann F Sullivan, and Anthony H Dickenson
February 1996, The Journal of pharmacology and experimental therapeutics,
Louise C Stanfa, and Ann F Sullivan, and Anthony H Dickenson
December 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience,
Louise C Stanfa, and Ann F Sullivan, and Anthony H Dickenson
June 1994, The Journal of pharmacology and experimental therapeutics,
Louise C Stanfa, and Ann F Sullivan, and Anthony H Dickenson
September 1995, Masui. The Japanese journal of anesthesiology,
Louise C Stanfa, and Ann F Sullivan, and Anthony H Dickenson
January 1997, Life sciences,
Louise C Stanfa, and Ann F Sullivan, and Anthony H Dickenson
August 1997, Brain research,
Louise C Stanfa, and Ann F Sullivan, and Anthony H Dickenson
August 1985, The Journal of pharmacology and experimental therapeutics,
Louise C Stanfa, and Ann F Sullivan, and Anthony H Dickenson
October 1990, Brain research,
Louise C Stanfa, and Ann F Sullivan, and Anthony H Dickenson
September 1991, British journal of pharmacology,
Louise C Stanfa, and Ann F Sullivan, and Anthony H Dickenson
July 1994, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!